Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.55% |
| 2 | Consumer Discretionary | 0.95% |
| 3 | Financials | 0.77% |
| 4 | Healthcare | 0.67% |
| 5 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
12076
PharmaCyte Biotech
PMCB
$5.79M
| $23K | ﹤0.01% |
18,406
-16,075
| -47% | -$26.1K |
|
12077
Asia Pacific Wire & Cable
APWC
$58.6M
| $23K | ﹤0.01% |
+15,123
| New | +$23.3K |
|
12078
Bullfrog AI
BFRG
$10.8M
| $22.9K | ﹤0.01% |
+13,859
| New | +$32K |
|
|
IRD
12079
Opus Genetics
IRD
$342M
| $22.7K | ﹤0.01% |
+23,099
| New | +$25.8K |
|
12080
Compugen
CGEN
$272M
| $22.6K | ﹤0.01% |
+15,494
| New | +$30.2K |
|
|
KYNB
12081
PUT
Kyntra Bio
KYNB
$32.8M
| $22.5K | ﹤0.01% |
2,900
+268
| +10% | +$3.21K |
|
12082
PUT
W&T Offshore
WTI
$543M
| $22.5K | ﹤0.01% |
14,500
-600
| -4% | -$990 |
|
|
NB
12083
PUT
NioCorp Developments
NB
$651M
| $22.5K | ﹤0.01% |
11,400
+1,400
| +14% | +$2.81K |
|
|
IMMP
12084
PUT
Immutep
IMMP
$56.3M
| $22.4K | ﹤0.01% |
12,700
-34,500
| -73% | -$66.4K |
|
|
DRRX
12085
CALL
DELISTED
DURECT Corp
DRRX
| $22.3K | ﹤0.01% |
27,900
-25,200
| -47% | -$20.3K |
|
|
LDTC
12086
DELISTED
LeddarTech
LDTC
| $22.2K | ﹤0.01% |
48,338
| – | – |
|
|
ENZ
12087
DELISTED
Enzo Biochem, Inc.
ENZ
| $22.2K | ﹤0.01% |
60,041
+26,206
| +77% | +$14.5K |
|
|
VTYX
12088
PUT
DELISTED
Ventyx Biosciences
VTYX
| $22.1K | ﹤0.01% |
19,200
-69,700
| -78% | -$120K |
|
|
UBX
12089
PUT
DELISTED
Unity Biotechnology
UBX
| $22K | ﹤0.01% |
+21,200
| New | +$38.3K |
|
12090
CALL
Alto Neuroscience
ANRO
$1.42B
| $22K | ﹤0.01% |
10,200
-1,400
| -12% | -$5.01K |
|
|
YQ
12091
PUT
17 Education & Technology Group
YQ
$21.6M
| $21.8K | ﹤0.01% |
+11,300
| New | +$21.4K |
|
12092
PUT
Invivyd
IVVD
$277M
| $21.6K | ﹤0.01% |
+35,400
| New | +$31.8K |
|
12093
OPAL Fuels
OPAL
$64.7M
| $21.6K | ﹤0.01% |
11,728
-13,491
| -53% | -$36.9K |
|
12094
PUT
Purple Innovation
PRPL
$20.7M
| $21.4K | ﹤0.01% |
1,128
-92
| -8% | -$2.12K |
|
12095
PUT
Outlook Therapeutics
OTLK
$155M
| $21.2K | ﹤0.01% |
+17,400
| New | +$30.5K |
|
12096
Generation Income Properties
GIPR
$990K
| $21.2K | ﹤0.01% |
+1,326
| New | +$22.6K |
|
12097
CALL
Lexicon Pharmaceuticals
LXRX
$1.04B
| $21.2K | ﹤0.01% |
+46,100
| New | +$29.1K |
|
12098
PUT
Skye Bioscience
SKYE
$8.94M
| $21.1K | ﹤0.01% |
+1,663
| New | +$36.3K |
|
|
TOUR
12099
PUT
Tuniu
TOUR
$52.6M
| $21K | ﹤0.01% |
+1,910
| New | +$19.7K |
|
12100
Rani Therapeutics
RANI
$103M
| $20.9K | ﹤0.01% |
+16,554
| New | +$24.5K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass withdrew a net $24.4B in Q1 2025, closing 1,482 positions and reducing 4,842 holdings. Its most notable exit was Inari Medical, Inc. Common Stock, an estimated $24M position sold in full.
By sector, the portfolio is most concentrated in Technology at 1.6% of assets, down from 2% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jeff Yass opened a new position in Brookfield Asset Management worth $86M.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.